NCT06498622 2024-07-12Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabAnhui Provincial HospitalPhase 2 Recruiting45 enrolled
NCT05545124 2022-09-19Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of RecurrenceHenan Cancer HospitalPhase 2 Unknown32 enrolled